Development of a RNA-Seq Based Prognostic Signature for Lung Cancer

October 7, 2016 Leave a comment 4,224 Views

Precision therapy for lung cancer will require comprehensive genomic testing to identify actionable targets as well as ascertain disease prognosis. RNA-seq is a robust platform that meets these requirements, but microarray-derived prognostic signatures are not optimal for RNA-seq data. Thus, ...

RNA-Seq Blog Transcriptome Research & Industry News

Tag Archives: Prognostic Signature

Development of a RNA-Seq Based Prognostic Signature for Lung Cancer

The history of spatial transcriptomics

MagBio Genomics Inc. develops automated RNA purification chemistry

Mindera raises over $12M to commercialize an RNA sequencing based skin test

A robust method of nuclei isolation for single-cell RNA sequencing of solid plant tissues

Zymo Research releases bioinformatics pipeline for SARS-CoV-2 variant detection

Integrating barcoded neuroanatomy with spatial transcriptional profiling

Single-cell map of early stage lung cancer and normal lung sheds light on tumor development, new therapeutic targets